Carmen J Allegra

Summary

Affiliation: University of Florida
Country: USA

Publications

  1. pmc Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial
    Carmen J Allegra
    NRG Oncology National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA CJA, Gy, MJO, RWB, TFW, HCP, AFS, JCL, DPR, AA, LSE, NB, gs, JFE, JMR, DFMJr, MRM, BTM, PJW, SS, MSR, NW Department of Medicine, University of Florida Health, Gainesville, FL CJA NRG Oncology and the University of Pittsburgh Graduate School of Public Health, Department of Biostatistics, Pittsburgh, PA GY Glendale Memorial Hospital, Glendale, CA RWB CCOP Christiana Care Health Systems, Newark, DE TFW Mayo Clinic, Rochester, The Ohio State University
    J Natl Cancer Inst 107:. 2015
  2. pmc Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial
    Carmen J Allegra
    University of Florida, Division of Hematology and Oncology, 1600 SW Archer Ave, Rm N 503, Gainesville, FL 32610, USA
    J Clin Oncol 31:359-64. 2013
  3. pmc Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer
    Carmen J Allegra
    Department of Biostatistics, University of Pittsburgh, PA, USA
    J Clin Oncol 27:3385-90. 2009
  4. doi request reprint National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009
    Carmen J Allegra
    University of Florida Shands Cancer Center, Department of Medicine, University of Florida, Gainesville, FL 32610, USA
    J Natl Cancer Inst 102:161-9. 2010
  5. pmc Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08
    Carmen J Allegra
    University of Florida, Division of Hematology and Oncology, 1600 SW Archer Ave, Rm N 503, Gainesville, FL 32610, USA
    J Clin Oncol 29:11-6. 2011
  6. pmc Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses
    Greg Yothers
    NSABP Biostatistical Center, One Sterling Plaza, 201 N Craig St, STE 350, Pittsburgh, PA 15213, USA
    J Clin Oncol 29:3768-74. 2011
  7. pmc Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03
    Mark S Roh
    National Surgical Adjuvant Breast and Bowel Project NSABP Operations Cente, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, USA
    J Clin Oncol 27:5124-30. 2009
  8. ncbi request reprint NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS)
    Carmen J Allegra
    University of Florida Shands Cancer Center, University of Florida, Gainesville, Florida, USA
    NIH Consens State Sci Statements 26:1-27. 2009
  9. pmc Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials
    Frank A Sinicrope
    North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 30:406-12. 2012
  10. doi request reprint Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials
    Frank A Sinicrope
    Department of Medicine, Mayo Clinic, Rochester, Minnesota2Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, Minnesota
    JAMA Oncol . 2016

Detail Information

Publications16

  1. pmc Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial
    Carmen J Allegra
    NRG Oncology National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA CJA, Gy, MJO, RWB, TFW, HCP, AFS, JCL, DPR, AA, LSE, NB, gs, JFE, JMR, DFMJr, MRM, BTM, PJW, SS, MSR, NW Department of Medicine, University of Florida Health, Gainesville, FL CJA NRG Oncology and the University of Pittsburgh Graduate School of Public Health, Department of Biostatistics, Pittsburgh, PA GY Glendale Memorial Hospital, Glendale, CA RWB CCOP Christiana Care Health Systems, Newark, DE TFW Mayo Clinic, Rochester, The Ohio State University
    J Natl Cancer Inst 107:. 2015
    ....
  2. pmc Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial
    Carmen J Allegra
    University of Florida, Division of Hematology and Oncology, 1600 SW Archer Ave, Rm N 503, Gainesville, FL 32610, USA
    J Clin Oncol 31:359-64. 2013
    ..Our report summarizes the primary and secondary end points of disease-free and overall survival, respectively, with 5 years median follow-up time...
  3. pmc Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer
    Carmen J Allegra
    Department of Biostatistics, University of Pittsburgh, PA, USA
    J Clin Oncol 27:3385-90. 2009
    ..We present safety information in advance of the planned analysis of efficacy...
  4. doi request reprint National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009
    Carmen J Allegra
    University of Florida Shands Cancer Center, Department of Medicine, University of Florida, Gainesville, FL 32610, USA
    J Natl Cancer Inst 102:161-9. 2010
    ..To provide health-care providers, patients, and the general public with a responsible assessment of currently available data on the diagnosis and management of ductal carcinoma in situ (DCIS)...
  5. pmc Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08
    Carmen J Allegra
    University of Florida, Division of Hematology and Oncology, 1600 SW Archer Ave, Rm N 503, Gainesville, FL 32610, USA
    J Clin Oncol 29:11-6. 2011
    ....
  6. pmc Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses
    Greg Yothers
    NSABP Biostatistical Center, One Sterling Plaza, 201 N Craig St, STE 350, Pittsburgh, PA 15213, USA
    J Clin Oncol 29:3768-74. 2011
    ..This analysis is the first publication of overall survival (OS) for the NSABP C-07 study. We updated DFS and examined both end points in clinically relevant patient subsets...
  7. pmc Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03
    Mark S Roh
    National Surgical Adjuvant Breast and Bowel Project NSABP Operations Cente, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, USA
    J Clin Oncol 27:5124-30. 2009
    ..The NSABP R-03 (National Surgical Adjuvant Breast and Bowel Project R-03) trial compared neoadjuvant versus adjuvant chemoradiotherapy in the treatment of locally advanced rectal carcinoma...
  8. ncbi request reprint NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS)
    Carmen J Allegra
    University of Florida Shands Cancer Center, University of Florida, Gainesville, Florida, USA
    NIH Consens State Sci Statements 26:1-27. 2009
    ..To provide health care providers, patients, and the general public with a responsible assessment of currently available data on the diagnosis and management of ductal carcinoma in situ (DCIS)...
  9. pmc Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials
    Frank A Sinicrope
    North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 30:406-12. 2012
    ..Although the importance of obesity in colon cancer risk and outcome is recognized, the association of body mass index (BMI) with DNA mismatch repair (MMR) status is unknown...
  10. doi request reprint Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials
    Frank A Sinicrope
    Department of Medicine, Mayo Clinic, Rochester, Minnesota2Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, Minnesota
    JAMA Oncol . 2016
    ..The association of biomarkers with patient survival after recurrence (SAR) of cancer is poorly understood but may guide management and treatment...
  11. ncbi request reprint Thymidylate synthase expression in colon carcinomas with microsatellite instability
    Frank A Sinicrope
    Mayo Clinic and Mayo College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 12:2738-44. 2006
    ..Given that thymidylate synthase (TS) is inhibited by 5-FU, we studied the relationship between MSI and TS expression, and the prognostic effect of these and other markers (i.e., p53 and 17p allelic imbalance)...
  12. pmc ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer
    Lindsay A Renfro
    Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN LAR, DJS Department of Oncology, Mayo Clinic, Rochester, MN AMG, SRA, CLL Department of Statistics, University of Virginia, Charlottesville, VA YX Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY LBS Hôpital Saint Antoine, Paris, France Pierre and Marie Curie University, Paris, France TA Leeds Institute of Cancer and Pathology, University of Leeds and St James s University Hospital, Leeds Cancer Research UK Centre, UK CT Oncology Unit, Ospedale Giovanni XXIII, Bergamo, Italy RL Division of Hematology and Oncology, University of Florida, Gainesville, FL CJA National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Pittsburgh, PA GY
    J Natl Cancer Inst 106:. 2014
    ....
  13. doi request reprint American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
    Carmen J Allegra
    Division of Hematology Oncology, Department of Medicine, University of Florida Shands CancerCenter, Gainesville, FL, USA
    J Clin Oncol 27:2091-6. 2009
    ....
  14. pmc Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database
    Manish A Shah
    Manish A Shah, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY Lindsay A Renfro, Steven R Alberts, and Daniel J Sargent, Mayo Clinic, Rochester, MN Carmen J Allegra, University of Florida, Gainesville, FL Thierry André, Hopital Saint Antoine, Paris Aimery de Gramont, Franco British Institute, Levallois Perret, France Hans Joachim Schmoll, University Clinic Halle Saale, Halle, Germany Daniel G Haller, University of Pennsylvania, Philadelphia and Greg Yothers, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA
    J Clin Oncol 34:843-53. 2016
    ..The impact of oxaliplatin added to FU + LV on the time course of recurrence and survival remains unknown...
  15. doi request reprint Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015
    Carmen J Allegra
    Carmen J Allegra, University of Florida, Gainesville, FL R Bryan Rumble, Pamela B Mangu, and Richard L Schilsky, American Society of Clinical Oncology Nancy Roach, Fight Colorectal Cancer, Alexandria, VA Stanley R Hamilton, University of Texas MD Anderson Cancer Center, Houston, TX and Alexander Hantel, Edward Cancer Center, Naperville, IL
    J Clin Oncol 34:179-85. 2016
    ..This PCO update addresses the utility of extended RAS gene mutation testing in patients with metastatic colorectal cancer (mCRC) to detect resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MoAb) therapy...
  16. pmc Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials
    Thomas J George
    University of Florida Health Cancer Center, Gainesville, 1600 SW Archer Rd, PO Box 100278, Gainesville, FL 32610 USA NRG Oncology, Four Penn Center, 1600 JFK Blvd, Suite 1020, Philadelphia, PA 19103 USA
    Curr Colorectal Cancer Rep 11:275-280. 2015
    ..While final dataset validation is ongoing, the NAR score offers an opportunity to incorporate a novel surrogate endpoint into early phase rectal cancer clinical trials...